Piramal Pharma's long term prospects are intact. Though CDMO growth in FY26 is muted, management has reiterated its FY30 aspirational revenue...
Piramal Pharma is seeing strong momentum in CDMO. Postponement of the Biosecure Act is unlikely to cause growth related issues as China...
Piramal Pharma is a conviction pick. Co is at critical inflection point. Overall improvement is expected as CDMO momentum continues. Complex...
Buy Piramal Pharma for TP of 200 (42% gain). Growing req for development services (complex regulatory processes for new drugs), high entry...
Separate names with a comma.